经审议, 本次监事会以通讯表决方式通过如下议案: 一、审议通过了《关于选举监事会主席的议案》 同意选举季华女士(简历详见附件)为公司监事会主席, 任期自本次监事会表 决通过之日起至第四届监事会任期届满为止。 证券代码：603718 证券简称：海利生物 公告编号：2023－029 上海海利生物技术股份有限公司 第四届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 上海海利生物技术股份有限公司(以下简称"公司")第四届监事会第十一次 会议通知于 2023 年 8 月 12 日以电子邮件和电话方式送达全体监事, 于 2023 年 8 月 18 日以通讯表决方式召开。本次监事会会议应参加监事 3 名, 实际参加监事 3 名。本次会议符合《中华人民共和国公司法》(以下简称"《公司法》")、《公司 章程》和《监事会议事规则》的有关规定, 会议的召集、召开合法有效。 二、监事会会议审议情况 因此, 监事会同意公司实施本次激励计划, 具体内容详见公司同日在上海证 券交易所网站(www. ...

证券简称：海利生物 证券代码：603718 上海荣正企业咨询服务（集团）股份有限公司 关于 上海海利生物技术股份有限公司 2023 年限制性股票与股票期权激励计划 （草案） 之 独立财务顾问报告 2023 年 8 月 | 一、释义 3 | | --- | | 二、声明 5 | | 三、基本假设 6 | | 四、独立财务顾问意见 7 | | （一） 对公司实行本激励计划条件的核查意见 7 | | （二） 对本激励计划内容及可行性的核查意见 7 | | （三） 对本激励计划激励对象范围和资格的核查意见 8 | | （四） 对股权激励计划权益授出额度的核查意见 8 | | （五） 对本激励计划授予价格定价方式的核查意见 9 | | （六） 对上市公司是否为激励对象提供任何形式的财务资助的核查意见 ... 10 | | （七） 对公司实施本激励计划的财务意见 11 | | （八） 公司实施本激励计划对上市公司持续经营能力、是否存在损害上市公 | | 司及全体股东利益的情形的核查意见 11 | | （九） 其他应当说明的事项 12 | | 五、备查文件及咨询方式 13 | | （一）备查文件 13 | 注：1、本报告所 ...

证券代码：603718 证券简称：海利生物 公告编号：2023－030 上海海利生物技术股份有限公司 2023 年限制性股票与股票期权激励计划 （草案）摘要的公告 法定代表人：张海明 注册资本：64,400万元人民币 成立日期：1981年7月18日 上市时间：2015年5月15日 经营范围：许可项目：兽药经营；第三类医疗器械经营；药品批发。（依法须经 批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准 文件或许可证件为准）一般项目：企业总部管理；信息咨询服务（不含许可类信息咨 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股权激励的权益总数及涉及的标的股票总数：本激励计划拟向激励对象授 予的股票权益合计 3,200 万股，约占本激励计划草案公告时公司股本总额 64,400 万股的 4.97%，不设置预留权益。 一、公司基本情况 （一）公司简介 公司名称：上海海利生物技术股份有限公司（以下简称"海利生物"、"公司" 或"本公司"） 2 公司目前监事会成员3人：季华、曹梅、周裕生。其中，季华 ...

star @ llinkslow Con SHANGHAI IQE ONE 111 HA711 68 Yin Chena Road M 上海市通力律师事务所 关于上海海利生物技术股份有限公司 2023 年限制性股票与股票期权激励计划的法律意见书 致:上海海利生物技术股份有限公司 敬启者: 上海市通力律师事务所(以下简称"本所")受上海海利生物技术股份有限公司(以下简称 "海利生物"或"公司")委托,指派张征轶律师、蔡丛丛律师(以下简称"本所律师")作为 公司特聘专项法律顾问,根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人 民共和国证券法》(以下简称"《证券法》")、中国证券监督管理委员会(以下简称"中国证监 会")发布的《上市公司股权激励管理办法》(以下简称"《管理办法》")、上海证券交易所发 布的《上海证券交易所股票上市规则(2023年2月修订)》(以下简称"《上市规则》")等法律、 行政法规和其他规范性文件(以下简称"法律、法规和规范性文件")和《上海海利生物技术 股份有限公司章程》(以下简称"《公司章程》")的有关规定,就海利生物拟实施之 2023 年 限制性股票与股票期权激励计划(以 ...

证券代码：603718 证券简称：海利生物 公告编号：2023-027 上海海利生物技术股份有限公司 2023 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 19 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 343,875,613 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 53.3968 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次年度股东大会由公司董事会召集，董事长张海明先生主持，采取现场加 网络投票方式召开并表决；会议的召集和召开符合《公司法》、《公司章程》和《股 东大会议事规则》的规定。 (一) 累积投票议案表决情况 1、 关于选举董事的议案 | 议案序号 | 议案名称 | 得票数 | 得票数占出席 | 是否当选 | | --- | --- | ...

每环留广场写字楼一期16-18层 7th Floor, One ICC, Shanghai ICC 99 Huai Hai Road 200031 Shanghai 北京市金杜律师事务所上海分所 关于上海海利生物技术股份有限公司 2023年第一次临时股东大会 之法律意见书 金杜律师事务所 KING&WCOD MAILESONS 致:上海海利生物技术股份有限公司 北京市金杜律师事务所上海分所(以下简称本所)接受上海海利生物技术股 份有限公司（以下简称公司）委托,根据《中华人民共和国证券法》(以下简称 《证券法》)、《中华人民共和国公司法》(以下简称《公司法》)、中国证券监督管 理委员会《上市公司股东大会规则(2022年修订)》(以下简称《股东大会规则》) 等中华人民共和国境内（以下简称中国境内,为本法律意见书之目的,不包括中 国香港特别行政区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行 政法规、规章和规范性文件和现行有效的《上海海利生物技术股份有限公司章程》 （以下简称《公司章程》）有关规定，指派律师出席了公司于 2023 年 8 月 17 日 召开的 2023年第一次临时股东大会(以下简称本次股东大 ...

上海海利生物技术股份有限公司 2023 年第一次临时股东大会 会议资料 二〇二三年八月 上海 上海海利生物技术股份有限公司 2023 年第一次临时股东大会议程 一、现场会议召开时间 2023 年 8 月 17 日（星期四）14:00 二、网络投票时间 1、互联网投票平台投票时间：2023 年 8 月 17 日的 9:15－15:00 2、交易系统投票平台投票时间：2023 年 8 月 17 日的交易时间段，即 9:15 －9:25，9:30－11:30，13:00－15:00 三、现场会议召开地点 四、会议主持 董事长张海明先生 五、会议议程 （一）董事长宣布 2023 年第一次临时股东大会开始，报告出席会议的股东 人数及代表股份总数 （二）介绍出席会议的董事、监事、高级管理人员、见证律师等人员情况 （三）推举两名监票人、一名计票人，并宣读议案审议和表决办法 （四）宣读和审议会议议案 1、关于选举董事的议案 2、关于选举监事的议案 上海市静安区南京西路 688 号 22 楼会议室 上述议案采用累积投票方式表决。 （五）股东发言、提问及公司回答 （六）现场会议投票表决 1、股东填写表决票 （七）董事长宣布现场会 ...

Financial Performance - The company achieved a net profit attributable to shareholders of the parent company of RMB 121,607,849.73 in 2022, with distributable profits for shareholders amounting to RMB 432,301,187.88[6]. - The company's operating revenue for 2022 was approximately ¥299.99 million, a decrease of 13.62% compared to ¥347.29 million in 2021[22]. - Net profit attributable to shareholders for 2022 was approximately ¥121.61 million, an increase of 125.80% from ¥53.86 million in 2021[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥24.81 million, up 9.22% from ¥22.72 million in 2021[22]. - The net cash flow from operating activities increased by 571.29% to approximately ¥292.91 million, primarily due to compensation received during the reporting period[23]. - The company's total assets at the end of 2022 were approximately ¥1.51 billion, a decrease of 17.89% from ¥1.84 billion at the end of 2021[22]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥1.14 billion, an increase of 13.40% from ¥1.01 billion at the end of 2021[22]. - The weighted average return on equity for 2022 was 11.33%, an increase of 6.36 percentage points from 4.97% in 2021[22]. - Basic earnings per share for 2022 were ¥0.19, a significant increase of 137.50% compared to ¥0.08 in 2021[22]. - The company reported a revenue increase of 15% year-over-year, reaching $500 million in Q3 2023[116]. Dividends and Profit Distribution - A cash dividend of RMB 0.567 per 10 shares (including tax) is proposed for the 2022 fiscal year[6]. - The company's cash dividend ratio for 2022 is 30.03%, with a total cash dividend amount of CNY 36,514,800[143]. - The profit distribution plan has been reviewed and deemed compliant with relevant laws and regulations, ensuring the protection of minority shareholders' interests[140]. Risk Management and Compliance - The company emphasizes the importance of risk management and has detailed various operational risks and corresponding mitigation strategies in the report[7]. - The company confirms no non-operating fund occupation by controlling shareholders or related parties[7]. - There are no violations of decision-making procedures regarding external guarantees[7]. - The internal control system has been continuously improved, with effective risk management and no significant deficiencies reported during the period[147]. - The company did not receive any penalties from securities regulatory authorities in the past three years[121]. Research and Development - The company aims to complete at least 5-10 new product trials annually, with ongoing R&D projects to support future growth[33]. - The company has established a stable cooperative relationship with various research institutions and universities, enhancing its research and development capabilities through a combination of independent and collaborative innovation[41]. - The company has developed multiple technology platforms, including antibody, molecular, and turbidimetric platforms, significantly improving product quality and cost control[41]. - The company is actively involved in various R&D projects, including the development of antibody detection kits and immunoglobulin assays, with several projects awaiting clinical evaluation[73][74]. - The company has successfully developed large-scale suspension culture technology and antigen purification technology, enhancing vaccine efficacy and production capacity[46]. Market and Industry Trends - The animal health industry in China has seen a compound annual growth rate (CAGR) of 8% over the past 12 years, with the animal vaccine market growing at a CAGR of 10%[35]. - The domestic IVD market is primarily concentrated in three areas: biochemical, immunological, and molecular diagnostics, with biochemical and immunological diagnostics accounting for 60% of the market share[37]. - The IVD industry is projected to continue evolving with new technologies and projects, emphasizing the importance of self-sufficiency in core raw materials for sustained development[92]. - The veterinary biological products market is undergoing a transformation from a "homogeneous price competition" model to a "quality and price improvement" model, driven by increased food safety awareness and government reforms[72]. Corporate Governance - The board of directors and supervisory board members have all attended the board meeting, ensuring accountability for the report's accuracy[4]. - The company has established a comprehensive performance evaluation system for senior management, linking their performance directly to compensation[145]. - The company has implemented a new senior management compensation assessment plan to enhance its incentive mechanisms[146]. - The company has not reported any objections from directors regarding company matters during the reporting period[124]. Environmental and Social Responsibility - The company has implemented carbon reduction measures, achieving a reduction of 105 tons of CO2 equivalent emissions through various energy-saving initiatives[159]. - The company has established an environmental management system in accordance with GB/T24001—2004/ISO14001:2004, with no environmental pollution incidents reported in 2022[165]. - The company actively participates in social welfare activities, including donations and support for vulnerable groups during the pandemic[167]. - The company donated materials worth RMB 71,000, including N95 masks valued at RMB 41,000 and hand sanitizer valued at RMB 30,000 during the pandemic[167]. Future Outlook and Strategic Initiatives - The company plans to enhance its governance structure and improve various systems in 2023 to ensure stable development while controlling risks[109]. - The company is exploring potential acquisitions to further enhance its product portfolio, with a budget of $100 million allocated for this purpose[116]. - The company plans to enhance its digital marketing strategy, aiming for a 40% increase in online sales[116]. - The company aims to enhance energy efficiency and has implemented a special fund for energy-saving measures, promoting comprehensive resource utilization[165].

Financial Performance - The company's operating revenue for Q1 2023 was ¥71,234,419.78, representing a decrease of 16.27% compared to the same period last year[4] - Net profit attributable to shareholders was ¥14,235,681.29, an increase of 34.35% year-on-year[4] - Basic earnings per share were ¥0.022, reflecting a growth of 34.35% year-on-year[4] - Net profit for Q1 2023 reached CNY 13,593,233.44, an increase of 20.6% from CNY 11,252,852.09 in Q1 2022[19] - The total comprehensive income attributable to the parent company for Q1 2023 was CNY 17,276,441.29, compared to CNY 6,141,464.08 in Q1 2022, representing an increase of approximately 180.5%[20] Cash Flow - The net cash flow from operating activities was -¥35,585,211.73, showing an increase in outflow of 30.65% compared to the previous year[4] - The net cash flow from operating activities for Q1 2023 was -CNY 35,585,211.73, an improvement from -CNY 51,314,739.29 in Q1 2022[22] - Cash inflow from operating activities totaled CNY 72,324,888.22 in Q1 2023, up from CNY 51,388,620.38 in Q1 2022, marking a growth of approximately 40.6%[22] - The company reported cash outflows from operating activities of CNY 107,910,099.95 in Q1 2023, slightly higher than CNY 102,703,359.67 in Q1 2022[22] - Investment activities generated a net cash flow of -CNY 42,177,186.39 in Q1 2023, an improvement from -CNY 60,197,781.91 in Q1 2022[22] - The company experienced a net decrease in cash and cash equivalents of -CNY 77,886,303.86 in Q1 2023, an improvement from -CNY 91,684,562.37 in Q1 2022[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,468,797,288.51, a decrease of 3.00% from the end of the previous year[5] - The company's total assets as of March 31, 2023, were CNY 1,468,797,288.51, a decrease from CNY 1,514,252,528.46 at the end of 2022[14] - Current assets totaled CNY 612,482,085.63, down from CNY 665,025,647.51 at the end of 2022, reflecting a decrease of 7.9%[14] - The total liabilities decreased to CNY 361,301,072.89 from CNY 403,249,280.19, a reduction of 10.4%[15] - The equity attributable to shareholders of the parent company was CNY 1,137,468,983.71, slightly down from CNY 1,140,333,568.51[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,356[8] - The largest shareholder, Shanghai Haoyuan Venture Investment Development Co., Ltd., held 35.12% of the shares[8] Investment Income - Non-recurring gains and losses totaled ¥3,052,426.34, with significant contributions from government subsidies and investment management gains[6] - The company reported an increase in net profit due to higher investment income recognized under the equity method[6] - The company reported a significant increase in investment income to CNY 2,832,581.91 from CNY 1,880,868.79, marking a rise of 50.7%[19] Revenue and Costs - Total operating costs for Q1 2023 were CNY 61,195,825.19, down 16.1% from CNY 72,908,621.76 in Q1 2022[19] - The company reported a total revenue from sales of goods and services of CNY 62,861,217.44 in Q1 2023, compared to CNY 44,085,140.12 in Q1 2022, reflecting an increase of approximately 42.6%[21]

投资者可于 2023 年 05 月 19 日（星期五） 至 05 月 25 日（星期四） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@hile-bio.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 上海海利生物技术股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 05 月 26 日下午 13:00-14:00 举行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 上海海利生物技术股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 证券代码：603718 证券简称：海利生物 公告编号：2023-016 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信 ...